Context: Reliable localization of insulinoma is critical for successful treatment. Objective: This study compared the accuracy of 68Gallium DOTA-(Tyr3)-octreotate (Ga-DOTATATE) positron emission tomography (PET)/computed tomography (CT) to anatomic imaging modalities, selective arterial secretagogue injection (SASI), and intraoperative ultrasound (IO ultrasound) and palpation for localizing insulinoma in patients who were biochemically cured. Design, Setting, and Patients: We conducted a retrospective analysis of 31 patients who had an insulinoma. The results of CT, magnetic resonance imaging (MRI), ultrasound, IO ultrasound, 68Ga-DOTATATE PET/CT, SASI, and operative findings were analyzed. Intervention, Main Outcome Measures, and Results: The insulinomas were correctly localized in 17 out of 31 (55%) patients by CT, in 17 out of 28 (61%) by MRI, in 6 out of 28 (21%) by ultrasound, and in 9 out of 10 (90%) by 68Ga-DOTATATE. In 29 of 31 patients (93.5%) who had IO ultrasound, an insulinoma was successfully localized. Thirty patients underwent SASI, and the insulinoma was regionalized in 28 out of 30 patients (93%). In 19 out of 23 patients (83%), manual palpation identified insulinoma. In patients who had all 4 noninvasive imaging studies, CT was concordant with 68Ga-DOTATATE in 6 out of 9 patients (67%), MRI in 8 out of 9 (78%), ultrasound in 0 out of 9; the lesion was only seen by 68Ga-DOTATATE in 1 out of 9 (11%). Conclusions: 68Ga-DOTATATE PET/CT identifies most insulinomas and may be considered as an adjunct imaging study when all imaging studies are negative and when a minimally invasive surgical approach is planned.
Context: Reliable localization of insulinoma is critical for successful treatment. Objective: This study compared the accuracy of 68Gallium DOTA-(Tyr3)-octreotate (Ga-DOTATATE) positron emission tomography (PET)/computed tomography (CT) to anatomic imaging modalities, selective arterial secretagogue injection (SASI), and intraoperative ultrasound (IO ultrasound) and palpation for localizing insulinoma in patients who were biochemically cured. Design, Setting, and Patients: We conducted a retrospective analysis of 31 patients who had an insulinoma. The results of CT, magnetic resonance imaging (MRI), ultrasound, IO ultrasound, 68Ga-DOTATATE PET/CT, SASI, and operative findings were analyzed. Intervention, Main Outcome Measures, and Results: The insulinomas were correctly localized in 17 out of 31 (55%) patients by CT, in 17 out of 28 (61%) by MRI, in 6 out of 28 (21%) by ultrasound, and in 9 out of 10 (90%) by 68Ga-DOTATATE. In 29 of 31 patients (93.5%) who had IO ultrasound, an insulinoma was successfully localized. Thirty patients underwent SASI, and the insulinoma was regionalized in 28 out of 30 patients (93%). In 19 out of 23 patients (83%), manual palpation identified insulinoma. In patients who had all 4 noninvasive imaging studies, CT was concordant with 68Ga-DOTATATE in 6 out of 9 patients (67%), MRI in 8 out of 9 (78%), ultrasound in 0 out of 9; the lesion was only seen by 68Ga-DOTATATE in 1 out of 9 (11%). Conclusions: 68Ga-DOTATATE PET/CT identifies most insulinomas and may be considered as an adjunct imaging study when all imaging studies are negative and when a minimally invasive surgical approach is planned.
Authors: B Hirshberg; A Livi; D L Bartlett; S K Libutti; H R Alexander; J L Doppman; M C Skarulis; P Gorden Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: Samira M Sadowski; Vladimir Neychev; Corina Millo; Joanna Shih; Naris Nilubol; Peter Herscovitch; Karel Pacak; Stephen J Marx; Electron Kebebew Journal: J Clin Oncol Date: 2015-12-28 Impact factor: 44.544
Authors: Samira M Sadowski; Corina Millo; Candice Cottle-Delisle; Roxanne Merkel; Lily A Yang; Peter Herscovitch; Karel Pacak; William F Simonds; Stephen J Marx; Electron Kebebew Journal: J Am Coll Surg Date: 2015-04-20 Impact factor: 6.113
Authors: Ronald C Walker; Gary T Smith; Eric Liu; Brandon Moore; Jeff Clanton; Michael Stabin Journal: J Nucl Med Date: 2013-03-20 Impact factor: 10.057
Authors: Jean-Marc Guettier; Anthony Kam; Richard Chang; Monica C Skarulis; Craig Cochran; H Richard Alexander; Steven K Libutti; James F Pingpank; Phillip Gorden Journal: J Clin Endocrinol Metab Date: 2009-02-03 Impact factor: 5.958
Authors: Benjamin Leroy-Freschini; Vincent Amodru; Pietro Addeo; Frédéric Sebag; Michel Vix; Laurent Brunaud; Marc Klein; Thibault Bahougne; Philippe Bachellier; Frédéric Castinetti; Bernard Goichot; Elodie Chevalier; David Taieb; Alessio Imperiale Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-07 Impact factor: 9.236
Authors: Katra Senica; Ales Tomazic; Ales Skvarca; Petra Kolenc Peitl; Renata Mikolajczak; Alicja Hubalewska-Dydejczyk; Luka Lezaic Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488